Mor Shlezinger
Hebrew University of Jerusalem
6 Papers
Mor Shlezinger is an academic researcher from Hebrew University of Jerusalem. The author has contributed to research in topics: Phage therapy & Enterococcus faecalis. The author has an hindex of 6, co-authored 6 publications.
Chat about Author
Papers
Phage therapy against Enterococcus faecalis in dental root canals
Leron Khalifa,Mor Shlezinger,Shaul Beyth,Yael Houri-Haddad,Shunit Coppenhagen-Glazer,Nurit Beyth,Ronen Hazan +6 more
TL;DR: The efforts to develop phage therapy against biofilms are reviewed and the possibility of using phages against E. faecalis biofilm in root canals is discussed, which is one of the most common threats observed in recurrent root canal treatment failures.
98
Defeating Antibiotic- and Phage-Resistant Enterococcus faecalis Using a Phage Cocktail in Vitro and in a Clot Model
Leron Khalifa,Daniel Gelman,Mor Shlezinger,Axel Lionel Dessal,Shunit Coppenhagen-Glazer,Nurit Beyth,Ronen Hazan +6 more
TL;DR: A new phage is isolated, EFLK1, which proved effective against both the resistant mutant EFDG1r and its parental VRE, Enterococcus faecalis V583, and combining both phages in a cocktail produced an additive effect against E. faecalia V583 strains regardless of their antibiotic or phage-resistance profile.
Phage Therapy: A New Horizon in the Antibacterial Treatment of Oral Pathogens.
Mor Shlezinger,Leron Khalifa,Yael Houri-Haddad,Shunit Coppenhagen-Glazer,Grégory Resch,Yok-Ai Que,Shaul Beyth,Elisheva Dorfman,Ronen Hazan,Nurit Beyth +9 more
TL;DR: The present review presents the etiology of common oral diseases, characterization of the infection and the treatment challenges of phage therapy in dentistry, as well as possibilities of engineering the oral microbiome.
53
Eradication of Vancomycin-Resistant Enterococci by Combining Phage and Vancomycin
TL;DR: Combinations of phage and vancomycin are highly efficient against VRE, despite being resistant to the antibiotic, and give hope in the continuous struggle against the current emergence of multidrug resistant pathogens.
51
Phages in a thermoreversible sustained-release formulation targeting E. faecalis in vitro and in vivo.
TL;DR: Poloxamer P407 formulated with phages has an effective and long-lasting effect in vitro and in vivo targeting E. faecalis and shows reduced periapical inflammation and improved healing following phage treatment.
45